 The primary objective of Phase 3 is to demonstrate that X4P-001 is an effective treatment for patients with WHIM syndrome, as demonstrated by sustained increases in circulating neutrophils and lymphocytes that are associated with improvements in clinical manifestations of WHIM syndrome. 